HomeAI · summaries
Storia in 2 fonti
Weight loss drug maker sinks 25% after new safety data spooks investors
While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
Nearly 1 in 5 patients quit Boehringer and Zealand’s obesity shot over side effects
Boehringer's survodutide showed 19% GI discontinuation rates in a Phase 3 obesity trial but was on par with Wegovy on weight loss.
- ·
cnbc.com
Weight loss drug maker sinks 25% after new safety data spooks investors
While the experimental drug met its key targets, analysts are concerned over the commercial opportunity due to side effects.